Details for Patent: 10,436,802

Which drugs does patent 10,436,802 protect, and when does it expire?

Patent 10,436,802 protects SPINRAZA and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 10,436,802

Title:	Methods for treating spinal muscular atrophy
Abstract:	Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
Inventor(s):	Rigo; Frank (Carlsbad, CA), Bishop; Katherine M. (San Diego, CA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	15/509,642
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,436,802

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes						TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes						TREATMENT OF SPINAL MUSCULAR ATROPHY
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes						TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY

Foreign Priority and PCT Information for Patent: 10,436,802

PCT Information
PCT Filed	September 11, 2015	PCT Application Number:	PCT/US2015/049598
PCT Publication Date:	March 17, 2016	PCT Publication Number:	WO2016/040748

International Family Members for US Patent 10,436,802

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112017004056
Chile	2017000594
Chile	2019000447